{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:35:45Z","timestamp":1787016945240,"version":"build-2736575974"},"reference-count":46,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["106-2314-B-002-138-MY3"],"award-info":[{"award-number":["106-2314-B-002-138-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["107-2314-B-002-038-MY2"],"award-info":[{"award-number":["107-2314-B-002-038-MY2"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2020,12,23]]},"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Data regarding the real-world effectiveness and safety of sofosbuvir\/velpatasvir (SOF\/VEL) with or without low-dose ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) infection and severe renal impairment (RI) are limited. We evaluated the performance of SOF\/VEL with or without low-dose RBV in HCV-infected patients with chronic kidney disease stage 4 or 5.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>\n                      191 patients with compensated (n=181) and decompensated (n=10) liver diseases receiving SOF\/VEL (400\/100\u2009mg\/day) alone and SOF\/VEL with low-dose RBV (200\u2009mg\/day) for 12 weeks were retrospectively recruited at 15 academic centres in Taiwan. The effectiveness was determined by sustained virological response at off-treatment week 12 (SVR\n                      <jats:sub>12<\/jats:sub>\n                      ) in evaluable (EP) and per-protocol populations (PP). The safety profiles were assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The SVR\n                      <jats:sub>12<\/jats:sub>\n                      rates by EP and PP analyses were 94.8% (95% CI 90.6% to 97.1%) and 100% (95% CI 97.9% to 100%). In patients with compensated liver disease, the SVR\n                      <jats:sub>12<\/jats:sub>\n                      rates were 95.0% and 100% by EP and PP analyses. In patients with decompensated liver disease, the SVR\n                      <jats:sub>12<\/jats:sub>\n                      rates were 90.0% and 100% by EP and PP analyses. Ten patients who failed to achieve SVR\n                      <jats:sub>12<\/jats:sub>\n                      were attributed to non-virological failures. Among the 20 serious adverse events (AEs), none were judged related to SOF\/VEL or RBV. The AEs occurring in \u226510% included fatigue (14.7%), headache (14.1%), nausea (12.6%), insomnia (12.0%) and pruritus (10.5%). None had \u2265grade 3 total bilirubin or alanine aminotransferase elevations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SOF\/VEL with or without low-dose RBV is effective and well-tolerated in HCV-infected patients with severe RI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2020-323569","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T15:55:26Z","timestamp":1609948526000},"page":"176-184","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["Sofosbuvir\/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment"],"prefix":"10.1136","volume":"71","author":[{"given":"Chen-Hua","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Yunlin, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Yi","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Wen","family":"Su","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4811-3018","authenticated-orcid":false,"given":"Kuo-Chih","family":"Tseng","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan"},{"name":"School of Medicine, Tzuchi University, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Chu","family":"Lo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, St. Martin De Porres Hospital, Daya, Chiayi, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyh-Jou","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Chi-Mei Medical Center, Liouying, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9030-6086","authenticated-orcid":false,"given":"Cheng-Yuan","family":"Peng","sequence":"additional","affiliation":[{"name":"Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan"},{"name":"School of Medicine, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Lueng","family":"Shih","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Shun","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan"},{"name":"School of Medicine, Chung Shan Medical University, Taichung, Taiwan"},{"name":"Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Sheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Yang Ming Hospital, Chiayi, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Jhang","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, China Medical University Beigang Hospital, Yunlin, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Yang","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Fu Jen Catholic University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chang","family":"Tsai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Yu","family":"Kao","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan"},{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"},{"name":"Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo-Jen","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Yunlin, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Yueh","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Yuan","family":"Su","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6951-4646","authenticated-orcid":false,"given":"Chih-Wei","family":"Tseng","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan"},{"name":"School of Medicine, Tzuchi University, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jow-Jyh","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, St. Martin De Porres Hospital, Daya, Chiayi, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Lun","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Chi-Mei Medical Center, Liouying, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsueh-Chou","family":"Lai","sequence":"additional","affiliation":[{"name":"Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan"},{"name":"School of Medicine, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsai-Yuan","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Hsin","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jie","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Jen","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Fu Jen Catholic University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3396-1559","authenticated-orcid":false,"given":"Chun-Chao","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan"},{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"},{"name":"Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-7952","authenticated-orcid":false,"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"2025112505460805000_71.1.176.1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/ki.2013.455","article-title":"A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease","volume":"85","author":"Chen","year":"2014","journal-title":"Kidney Int"},{"key":"2025112505460805000_71.1.176.2","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2215\/CJN.01530218","article-title":"Kidney function decline in patients with CKD and untreated hepatitis C infection","volume":"13","author":"Tartof","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025112505460805000_71.1.176.3","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1440-1746.2010.06488.x","article-title":"Treatment of hepatitis C virus infection in patients with end-stage renal disease","volume":"26","author":"Liu","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"2025112505460805000_71.1.176.4","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.kint.2018.11.038","article-title":"Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients","volume":"95","author":"Jadoul","year":"2019","journal-title":"Kidney Int"},{"key":"2025112505460805000_71.1.176.5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025112505460805000_71.1.176.6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.4254\/wjh.v9.i19.833","article-title":"Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease","volume":"9","author":"Ladino","year":"2017","journal-title":"World J Hepatol"},{"key":"2025112505460805000_71.1.176.7","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2893.2012.01633.x","article-title":"Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?","volume":"19","author":"Fabrizi","year":"2012","journal-title":"J Viral Hepat"},{"key":"2025112505460805000_71.1.176.8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2215\/CJN.07940716","article-title":"Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis","volume":"12","author":"Goodkin","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025112505460805000_71.1.176.9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000355615","article-title":"Hepatitis C infection is very rarely treated among hemodialysis patients","volume":"38","author":"Goodkin","year":"2013","journal-title":"Am J Nephrol"},{"key":"2025112505460805000_71.1.176.10","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002113","article-title":"Interferon-Based treatment of hepatitis C virus infection reduces all-cause mortality in patients with end-stage renal disease: an 8-year nationwide cohort study in Taiwan","volume":"94","author":"Hsu","year":"2015","journal-title":"Medicine"},{"key":"2025112505460805000_71.1.176.11","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.2215\/CJN.00410111","article-title":"Long-Term viral negativity after interferon for chronic hepatitis C virus infection in hemodialysis","volume":"6","author":"Gordon","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025112505460805000_71.1.176.12","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jhep.2018.12.036","article-title":"Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation","volume":"70","author":"Fontaine","year":"2019","journal-title":"J Hepatol"},{"key":"2025112505460805000_71.1.176.13","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jhep.2019.07.021","article-title":"Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations","volume":"71","author":"Rossi","year":"2019","journal-title":"J Hepatol"},{"key":"2025112505460805000_71.1.176.14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.kint.2019.04.030","article-title":"Direct-Acting antiviral therapy slows kidney function decline in patients with hepatitis C virus infection and chronic kidney disease","volume":"97","author":"Sise","year":"2020","journal-title":"Kidney Int"},{"key":"2025112505460805000_71.1.176.15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/liv.14363","article-title":"Micro-elimination of hepatitis C virus","volume":"40 Suppl 1","author":"Hollande","year":"2020","journal-title":"Liver Int"},{"key":"2025112505460805000_71.1.176.16","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","volume":"67","author":"Chung","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025112505460805000_71.1.176.17","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"European association for the study of the liver. EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"2025112505460805000_71.1.176.18","unstructured":"Geneva: World Health Organization . Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection, 2018. Available: https:\/\/www.who.int\/hepatitis\/publications\/hepatitis-c-guidelines-2018\/en\/ [Accessed 22 October 2020]."},{"key":"2025112505460805000_71.1.176.19","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s40265-014-0247-z","article-title":"Sofosbuvir: a review of its use in patients with chronic hepatitis C","volume":"74","author":"Keating","year":"2014","journal-title":"Drugs"},{"key":"2025112505460805000_71.1.176.20","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s40265-016-0648-2","article-title":"Sofosbuvir\/velpatasvir: a review in chronic hepatitis C","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"2025112505460805000_71.1.176.21","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(12)61113-1","article-title":"1101 the effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977","volume":"56","author":"Cornpropst","year":"2012","journal-title":"J Hepatol"},{"key":"2025112505460805000_71.1.176.22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","article-title":"Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C","volume":"65","author":"Desnoyer","year":"2016","journal-title":"J Hepatol"},{"key":"2025112505460805000_71.1.176.23","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2019.05.028","article-title":"Sofosbuvir\/velpatasvir for 12\u202fweeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis","volume":"71","author":"Borgia","year":"2019","journal-title":"J Hepatol"},{"key":"2025112505460805000_71.1.176.24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jceh.2019.10.004","article-title":"Sofosbuvir-Velpatasvir fixed drug combination for the treatment of chronic hepatitis C infection in patients with end-stage renal disease and kidney transplantation","volume":"10","author":"Gaur","year":"2020","journal-title":"J Clin Exp Hepatol"},{"key":"2025112505460805000_71.1.176.25","doi-asserted-by":"crossref","unstructured":"Taneja S , Duseja A , Mehta M , et al . Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end\u2010stage renal disease on maintenance hemodialysis. Liver International 2020.doi:10.1111\/liv.14685","DOI":"10.1111\/liv.14685"},{"key":"2025112505460805000_71.1.176.26","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"CKD-EPI (chronic kidney disease epidemiology collaboration). A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2025112505460805000_71.1.176.27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-137-1-200207020-00006","article-title":"Updated definitions of healthy ranges for serum alanine aminotransferase levels","volume":"137","author":"Prati","year":"2002","journal-title":"Ann Intern Med"},{"key":"2025112505460805000_71.1.176.28","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1128\/JCM.03548-14","article-title":"Comparison of Abbott RealTime HCV genotype II with Versant line probe assay 2.0 for hepatitis C virus genotyping","volume":"53","author":"Liu","year":"2015","journal-title":"J Clin Microbiol"},{"key":"2025112505460805000_71.1.176.29","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"2025112505460805000_71.1.176.30","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"2025112505460805000_71.1.176.31","unstructured":"FDA U.S . Food and drug administration. Copegus (ribavirin) tablet label, 2020. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021511s023lbl.pdf [Accessed 28 October 2020]."},{"key":"2025112505460805000_71.1.176.32","doi-asserted-by":"crossref","first-page":"729","DOI":"10.7326\/0003-4819-159-11-201312030-00005","article-title":"Pegylated interferon-\u03b12a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial","volume":"159","author":"Liu","year":"2013","journal-title":"Ann Intern Med"},{"key":"2025112505460805000_71.1.176.33","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"2025112505460805000_71.1.176.34","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"ASTRAL-2 Investigators; ASTRAL-3 Investigators. sofosbuvir and Velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"key":"2025112505460805000_71.1.176.35","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"key":"2025112505460805000_71.1.176.36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/liv.14283","article-title":"Direct-Acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV-infected patients","volume":"40","author":"Ing Lorenzini","year":"2020","journal-title":"Liver Int"},{"key":"2025112505460805000_71.1.176.37","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/apt.15011","article-title":"Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan","volume":"48","author":"Liu","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112505460805000_71.1.176.38","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"International hepatitis Interventional therapy Group. adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"key":"2025112505460805000_71.1.176.39","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/gutjnl-2014-307080","article-title":"Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial","volume":"64","author":"Liu","year":"2015","journal-title":"Gut"},{"key":"2025112505460805000_71.1.176.40","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry","year":"2017","journal-title":"J Hepatol"},{"key":"2025112505460805000_71.1.176.41","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jhep.2019.11.014","article-title":"Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals","volume":"72","author":"Liu","year":"2020","journal-title":"J Hepatol"},{"key":"2025112505460805000_71.1.176.42","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/hep.29097","article-title":"Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: analysis of data from the Hepa-C registry","volume":"65","author":"Fern\u00e1ndez Carrillo","year":"2017","journal-title":"Hepatology"},{"key":"2025112505460805000_71.1.176.43","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/14737167.2019.1629291","article-title":"Cost-Effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic hepatitis C in the United States","volume":"20","author":"Gordon","year":"2020","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2025112505460805000_71.1.176.44","doi-asserted-by":"crossref","unstructured":"Chan J , Kim JJ , Barrett BK . Cost\u2010effectiveness analysis of sofosbuvir and Velpatasvir in chronic hepatitis C patients with decompensated cirrhosis. J Viral Hepat 2020;10.doi:10.1111\/jvh.13419","DOI":"10.1111\/jvh.13419"},{"key":"2025112505460805000_71.1.176.45","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","article-title":"Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis","volume":"3","author":"M\u00fccke","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025112505460805000_71.1.176.46","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx028","article-title":"Hepatitis B virus reactivation in patients receiving interferon-free direct-acting antiviral agents for chronic hepatitis C virus infection","volume":"4","author":"Liu","year":"2017","journal-title":"Open Forum Infect Dis"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2020-323569","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:49:38Z","timestamp":1764078578000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2020-323569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,8]]},"published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1136\/gutjnl-2020-323569"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2020-323569","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]}}}